Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

Cécile Pautas(Centre Hospitalier Universitaire Henri-Mondor), Sylvie Castaigné(Hôpital André Mignot)

Journal of Clinical Oncology

January 5, 2010

10.1200/jco.2009.23.2652

Cited by 217

Related Papers

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

|The Lancet|2012|994

A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

|Blood|1999|745

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

|Blood|2002|503

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

|Blood|2013|357

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

|Haematologica|2018|349